File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population

TitleActionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population
Authors
Editors
Editor(s):Limdi, N
Issue Date2021
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosgenetics.org/
Citation
PLoS Genetics, 2021, v. 17, p. article no. e1009323 How to Cite?
AbstractPharmacogenetic testing provides relevant drug phenotype information to guide personalized drug prescription, which potentially improves drug efficacy and prevent adverse drug reactions. However, its implementation in the Chinese population is limited by the lack of Chinese-specific pharmacogenetics data. In this study, we studied the spectrum of 133 actionable pharmacogenetic variants and rare deleterious variants in 108 pharmacogenes using an exome sequencing consisting of 1116 Hong Kong Chinese subjects. It was found that nearly all individuals carried at least one actionable pharmacogenetic variant and one rare, predicted deleterious pharmacogenetic variant. In addition, we projected the potential prescription impact of actionable pharmacogenetic variants using prescription data of the Hong Kong's public healthcare system. We estimated that one-seventh of the Hong Kong population received at least one of the 36 drugs with clinical pharmacogenetics guideline recommendations. The findings demonstrated the potential of pharmacogenetic testing in improving patient care and resource allocation in Chinese. The cohort dataset also supports clinical implementation of pharmacogenetics in the Chinese population. Preemptive pharmacogenetic testing has the potential to improve drug dosing by providing point-of-care patient genotype information. Nonetheless, its implementation in the Chinese population is limited by the lack of population-wide data. In this study, secondary analysis of exome sequencing data was conducted to study pharmacogenomics in 1116 Hong Kong Chinese. We aimed to identify the spectrum of actionable pharmacogenetic variants and rare, predicted deleterious variants that are potentially actionable in Hong Kong Chinese, and to estimate the proportion of dispensed drugs that may potentially benefit from genotype-guided prescription. The projected preemptive pharmacogenetic testing prescription impact was evaluated based on the patient prescription data of the public healthcare system in 2019, serving 7.5 million people. Twenty-nine actionable pharmacogenetic variants/ alleles were identified in our cohort. Nearly all (99.6%) subjects carried at least one actionable pharmacogenetic variant, whereas 93.5% of subjects harbored at least one rare deleterious pharmacogenetic variant. Based on the prescription data in 2019, 13.4% of the Hong Kong population was prescribed with drugs with pharmacogenetic clinical practice guideline recommendations. The total expenditure on actionable drugs was 33,520,000 USD, and it was estimated that 8,219,000 USD (24.5%) worth of drugs were prescribed to patients with an implicated actionable phenotype. Secondary use of exome sequencing data for pharmacogenetic analysis is feasible, and preemptive pharmacogenetic testing has the potential to support prescription decisions in the Hong Kong Chinese population.
Persistent Identifierhttp://hdl.handle.net/10722/297231
ISSN
2014 Impact Factor: 7.528
2020 SCImago Journal Rankings: 3.587
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYU, MHC-
dc.contributor.authorChan, MCY-
dc.contributor.authorCHUNG, CCY-
dc.contributor.authorLi, AWT-
dc.contributor.authorYip, CYW-
dc.contributor.authorMak, CCY-
dc.contributor.authorCHAU, JFT-
dc.contributor.authorLEE, M-
dc.contributor.authorFung, JLF-
dc.contributor.authorTSANG, MHY-
dc.contributor.authorChan, JCK-
dc.contributor.authorWong, WHS-
dc.contributor.authorYang, J-
dc.contributor.authorChui, WCM-
dc.contributor.authorChung, PHY-
dc.contributor.authorYang, W-
dc.contributor.authorLee, SL-
dc.contributor.authorChan, GCF-
dc.contributor.authorTam, PKH-
dc.contributor.authorLau, YL-
dc.contributor.authorTang, CSM-
dc.contributor.authorYeung, KS-
dc.contributor.authorChung, BHY-
dc.contributor.editorLimdi, N-
dc.date.accessioned2021-03-08T07:16:01Z-
dc.date.available2021-03-08T07:16:01Z-
dc.date.issued2021-
dc.identifier.citationPLoS Genetics, 2021, v. 17, p. article no. e1009323-
dc.identifier.issn1553-7390-
dc.identifier.urihttp://hdl.handle.net/10722/297231-
dc.description.abstractPharmacogenetic testing provides relevant drug phenotype information to guide personalized drug prescription, which potentially improves drug efficacy and prevent adverse drug reactions. However, its implementation in the Chinese population is limited by the lack of Chinese-specific pharmacogenetics data. In this study, we studied the spectrum of 133 actionable pharmacogenetic variants and rare deleterious variants in 108 pharmacogenes using an exome sequencing consisting of 1116 Hong Kong Chinese subjects. It was found that nearly all individuals carried at least one actionable pharmacogenetic variant and one rare, predicted deleterious pharmacogenetic variant. In addition, we projected the potential prescription impact of actionable pharmacogenetic variants using prescription data of the Hong Kong's public healthcare system. We estimated that one-seventh of the Hong Kong population received at least one of the 36 drugs with clinical pharmacogenetics guideline recommendations. The findings demonstrated the potential of pharmacogenetic testing in improving patient care and resource allocation in Chinese. The cohort dataset also supports clinical implementation of pharmacogenetics in the Chinese population. Preemptive pharmacogenetic testing has the potential to improve drug dosing by providing point-of-care patient genotype information. Nonetheless, its implementation in the Chinese population is limited by the lack of population-wide data. In this study, secondary analysis of exome sequencing data was conducted to study pharmacogenomics in 1116 Hong Kong Chinese. We aimed to identify the spectrum of actionable pharmacogenetic variants and rare, predicted deleterious variants that are potentially actionable in Hong Kong Chinese, and to estimate the proportion of dispensed drugs that may potentially benefit from genotype-guided prescription. The projected preemptive pharmacogenetic testing prescription impact was evaluated based on the patient prescription data of the public healthcare system in 2019, serving 7.5 million people. Twenty-nine actionable pharmacogenetic variants/ alleles were identified in our cohort. Nearly all (99.6%) subjects carried at least one actionable pharmacogenetic variant, whereas 93.5% of subjects harbored at least one rare deleterious pharmacogenetic variant. Based on the prescription data in 2019, 13.4% of the Hong Kong population was prescribed with drugs with pharmacogenetic clinical practice guideline recommendations. The total expenditure on actionable drugs was 33,520,000 USD, and it was estimated that 8,219,000 USD (24.5%) worth of drugs were prescribed to patients with an implicated actionable phenotype. Secondary use of exome sequencing data for pharmacogenetic analysis is feasible, and preemptive pharmacogenetic testing has the potential to support prescription decisions in the Hong Kong Chinese population.-
dc.languageeng-
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosgenetics.org/-
dc.relation.ispartofPLoS Genetics-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleActionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population-
dc.typeArticle-
dc.identifier.emailMak, CCY: ccymak@connect.hku.hk-
dc.identifier.emailFung, JLF: jasflf@connect.hku.hk-
dc.identifier.emailWong, WHS: whswong@hku.hk-
dc.identifier.emailYang, J: jingy09@hku.hk-
dc.identifier.emailChung, PHY: chungphy@hku.hk-
dc.identifier.emailYang, W: yangwl@hku.hk-
dc.identifier.emailLee, SL: slleem@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.emailTam, PKH: paultam@hku.hk-
dc.identifier.emailLau, YL: lauylung@hku.hk-
dc.identifier.emailTang, CSM: claratang@hku.hk-
dc.identifier.emailYeung, KS: ksyyeung@hku.hk-
dc.identifier.emailChung, BHY: bhychung@hku.hk-
dc.identifier.authorityChung, PHY=rp02002-
dc.identifier.authorityYang, W=rp00524-
dc.identifier.authorityChan, GCF=rp00431-
dc.identifier.authorityTam, PKH=rp00060-
dc.identifier.authorityLau, YL=rp00361-
dc.identifier.authorityTang, CSM=rp02105-
dc.identifier.authorityChung, BHY=rp00473-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1371/journal.pgen.1009323-
dc.identifier.pmid33600428-
dc.identifier.pmcidPMC7891783-
dc.identifier.hkuros321486-
dc.identifier.volume17-
dc.identifier.spagearticle no. e1009323-
dc.identifier.epagearticle no. e1009323-
dc.identifier.isiWOS:000620635100001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats